Continuous manufacturing is moving from an attractive concept to a mainstream production model for oral solid dose (OSD) medicines. Instead of producing tablets and capsules through a sequence of discrete batch steps, with material held, sampled and transferred between each stage, a continuous line feeds raw materials in at one end and delivers finished product at the other in an uninterrupted flow. This white paper explains why manufacturers are making the shift, how process analytical technology (PAT) underpins control, and what practical steps are involved in scaling from a pilot line to commercial supply.
Why Continuous Manufacturing Matters for Oral Solid Dose
Traditional batch processing for tablets typically involves dispensing, blending, granulation, drying, milling, compression and coating, each performed in separate equipment and often in separate rooms. Between steps, material waits in intermediate containers, creating hold times that add days or weeks to the overall cycle. Every transfer introduces variability, risk of segregation and opportunities for error. Continuous manufacturing integrates these unit operations so that material moves from feeders through a blender, optional granulation or direct compression, and on to compression and coating within a single connected train.
Quality Benefits
Because the process runs at steady state, every portion of the product experiences similar conditions. This reduces the batch-to-batch and within-batch variability that can arise when large volumes are blended and then compressed over many hours. Real-time monitoring allows deviations to be detected and corrected within minutes, and non-conforming material can be diverted from the stream automatically without discarding an entire batch.
Operational and Economic Benefits
A continuous line has a much smaller physical footprint than the equivalent batch suite. Because the same equipment can produce small quantities for clinical studies and large quantities for commercial supply simply by running for different lengths of time, manufacturers can respond to changing demand without installing new capacity. Reduced work-in-process inventory, shorter lead times and lower labor requirements all contribute to improved cost of goods.
- •Reduced cycle time from raw material to finished tablet
- •Smaller facility footprint and lower capital intensity per unit of output
- •Lower in-process inventory and fewer manual transfers
- •Greater flexibility to adjust output to demand
Core Building Blocks of a Continuous OSD Line
Feeding and Blending
Loss-in-weight feeders deliver active ingredient and excipients at precisely controlled rates. Feeder performance depends heavily on material flow properties, so powder characterization at an early stage is essential. Cohesive or electrostatic powders may require formulation adjustments or specialized feeder designs. The continuous blender then mixes the streams, and its residence time distribution determines how well it can dampen small fluctuations in feed rate.
Granulation, Direct Compression and Coating
Depending on the formulation, a line may use direct compression, continuous dry granulation by roller compaction, or twin-screw wet granulation followed by drying. Each route has different strengths. Direct compression is the simplest and shortest route but is only suitable for formulations with good flow and compactability. Twin-screw wet granulation expands the range of formulations that can be handled and produces granules with consistent properties. Downstream, a rotary tablet press and continuous coater complete the train.
Material Tracking and Batch Definition
A defining feature of continuous manufacturing is that a batch is defined by time or quantity rather than by vessel size. Robust material tracking, based on residence time distribution models, allows teams to know precisely which input materials ended up in which tablets. This traceability supports both quality decisions and regulatory discussions about batch definition.
Process Analytical Technology and Control Strategy
PAT is the nervous system of a continuous line. Near-infrared and Raman spectroscopy probes positioned after the blender measure active ingredient concentration and blend uniformity in real time. Tablet weight, hardness and thickness are monitored at the press, and automated feedback loops adjust feeder rates, compression force or fill depth to keep the process on target.
Multivariate Models
Spectral data are converted into quality predictions using multivariate calibration models. These models must be developed with representative samples spanning the expected operating range, validated against reference methods such as HPLC, and maintained throughout the product lifecycle. A disciplined model maintenance plan, including periodic verification and defined triggers for recalibration, protects against model drift.
Real-Time Release Testing
When PAT data and in-process controls are sufficiently robust, they can support real-time release testing (RTRT), in which finished product is released based on process data instead of, or in addition to, traditional end-product testing. RTRT can shorten release times from days to hours, reduce laboratory workload and lower inventory holding costs, but it requires a thoroughly justified and validated control strategy.
Handling Disturbances and Startup
Startup and shutdown phases produce material that does not meet specifications, so the control strategy must define how this transient material is identified and diverted. Intelligent diversion logic, combined with alarms and defined action limits, ensures that only conforming product proceeds downstream.
Scaling From Pilot to Commercial
One of the most attractive features of continuous manufacturing is that scale-up is achieved primarily by running longer, or by modestly increasing throughput, rather than by moving to larger equipment. Because the process geometry does not change, the understanding gained at pilot scale transfers directly to commercial operation.
Stage-Gated Approach
A pragmatic scale-up pathway begins with feasibility studies on a small-scale line using limited quantities of active ingredient. Once critical material attributes and process parameters are understood, the team moves to a development-scale line to establish the design space and test the control strategy. Commercial readiness is then confirmed through engineering and validation runs of the intended duration.
Technology Transfer
Because the same equipment platform is often used at development and commercial sites, technology transfer is simplified. Process recipes, control models and analytical methods can be transferred with minimal reinterpretation, shortening timelines and reducing the risk of unexpected differences.
Retrofitting and Hybrid Approaches
Not every product needs to be fully continuous. Many manufacturers adopt hybrid models, running continuous blending and compression while retaining batch granulation, or converting a single high-volume product first to build experience before extending to others. Existing products can be transitioned, but doing so requires a clear comparability strategy and regulatory planning.
Regulatory Considerations
Regulatory agencies in the United States, Europe and Asia have publicly encouraged adoption of advanced manufacturing. Guidance such as ICH Q13 on continuous manufacturing of drug substances and drug products provides a harmonized framework. Early dialogue with authorities is strongly advised, particularly around batch definition, process validation approach, handling of transient material and the use of RTRT.
Process Validation
Validation of a continuous process emphasizes ongoing verification rather than a fixed number of conformance batches. Demonstrating that the process remains in a state of control over extended runs, and that disturbances are detected and managed, forms the evidence base. Continued process verification then monitors performance throughout commercial life.
Documentation and Data Integrity
The volume of data generated by a continuous line is substantial. Reliable data acquisition, secure storage, audit trails and clear procedures for model changes are required to meet data integrity expectations.
Implementation Roadmap and Common Pitfalls
Successful adopters treat continuous manufacturing as a program rather than an equipment purchase. They build cross-functional teams spanning formulation, engineering, quality, regulatory and automation, and they invest in operator training. Common pitfalls include underestimating powder flow challenges, neglecting model maintenance, and failing to align quality systems with the new batch definition.
- •Characterize raw materials thoroughly before selecting a route
- •Define critical quality attributes and link them to monitored parameters
- •Plan PAT model development and lifecycle management from the start
- •Engage regulators early and document the batch definition clearly
- •Train operators to interpret trends rather than only react to alarms
Conclusion
Continuous manufacturing offers oral solid dose producers a route to higher quality, shorter cycle times and more flexible supply. With careful powder characterization, a sound PAT-based control strategy and a stage-gated scale-up plan, organizations can move from pilot to commercial scale with confidence, while meeting the expectations of global regulators.
About This White Paper
This white paper is published by Biotechnology Media Insights Editorial and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.